BioE®, Inc., and Phillips Plastics Corp.®, announced today they entered into a collaborative agreement to develop and commercialize stem cell therapeutics for orthopedic applications.

These stem cell therapeutics will consist of BioE’s highly functional proprietary Multi-Lineage Progenitor Cell™ (MLPC™) stem cell derived from human umbilical cord blood and Phillips Plastics’ patented and proprietary growth structures. In early development studies, the MLPC has differentiated into bone (osteoblasts) and cartilage (chondrocytes) progenitor cells, along with numerous other cell and tissue precursors. Phillips Plastics is developing custom structures to enhance the growth of these cells from the MLPC.

Orthopedic conditions affect upwards of 75 million Americans annually, making it one of the largest and rapidly growing sectors of U.S. medicine. According to industry analysts, the specific stem cell market for orthopedic applications could exceed $3 billion within the next 10 years, from less than $100 million today.

Link


  • Vesta Therapeutics Receives NIH Grant for Stem Cell Research for Liver diseases such as Hepatitis and Cirrhosis
  • Scientists Able to Turn Stem Cell Into Lung Cells
  • Stem Cell Therapeutics Corp To Present Phase I Intra-Muscular hCG Dose Study
  • ImmunoCellular Therapeutics Gets License From Cedars-Sinai Medical Center To Treat Cancer Stem Cell
  • Beware of International Stem Cell Scams
  • Cytori Therapeutics Has Sucessfully Implemented The Celution System
  • Stempeutics Launches Its Second Stem Cell research & therapeutics facility At Manipal; Bangalore
  • For The First Time Australia Uses Placenta Cord Blood For Stem Cell Research
  • Cloning Can Help Pet Lovers To Get Their Pet Back
  • Canada's First Umbilical Cord Tissue Stem Cell Bank